HTRS2025.P2.64 Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A or B on Fitusiran Antithrombin-Based Dosing Regimen (AT-DR): ATLAS-OLE
Makaleler > Tam Makale · 2025
Yazarlar: Amy Chen, Steven Pipe, Huyen Tran, Bulent Zulfikar, Chanchala Kaddi, Kaan Kavakli, Tadashi Matsushita, Mindy Simpson, Laurel A. Menapace, Marja Puurunen, Yuqian Shen, Meijing Wu, Vanessa Salinas
Research and Practice in Thrombosis and Haemostasis, Uluslararası, Wos, 2025, cilt 9, ss 103084-103084
DOI: 10.1016/j.rpth.2025.103084
Özet
Background: Fitusiran is a subcutaneous, investigational siRNA therapeutic that lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia A or B (PwHA/B), irrespective of inhibitor status. Phase 3 trials (ATLAS-INH [NCT03417102]; ATLAS A/B [NCT03417245]; ATLAS-PPX [NCT03549871]; ATLAS-OLE [NCT03754790]) demonstrated clinically meaningful bleed control with fitusiran. To treat bleeding events during fitusiran prophylaxis, bleed management guidelines (BMG) recommend reduced doses and frequencies of clotting factor concentrate (CFC)/ bypassing agents (BPA) as there is a potential for enhanced thrombin generation with concomitant use.